Drug
Lobeglitazone clinical trials
Also written CKD-501.
How studies write it
Studies that test it under each name
Studies by the year they started
30 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 3
Chong Kun Dang Pharmaceutical (27) · Seoul National University Bundang Hospital (2) · Pusan National University Hospital (1)
Often tested with
Tested in the same studies.
CKD-383 (3) · Sitagliptin (1) · Dapagliflozin (1) · D759 (1) · D745 (1) · Warfarin (1) · Ketoconazole (1) · Metformin (1)
Studies
Open first, then newest update. How each study uses lobeglitazone is read from its arms, and is right about nine times in ten.
Testing it · 30
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304700Written as CKD-501, D744, D150
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304687Written as CKD-501, D745, D150
- Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT07304726Written as CKD-501, D745, D150
- Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05897216Written as CKD-501, D745, D150, D029
- Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05816759Written as CKD-501, D744, D150
- Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg DuvieCompletedPhase 4Pusan National University HospitalNCT03770052Written as duvie
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedPhase 4Seoul National University Bundang HospitalNCT02338921Written as Lobeglitazone
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesCompletedPhase 3Chong Kun Dang PharmaceuticalNCT03739125Written as CKD-501 0.5mg
- A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04810676Written as CKD-501, D745, D150
- Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes ManagementStatus unknownPhase 4Seoul National University Bundang HospitalNCT02315287Written as Lobeglitazone
- Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393Status unknownPhase 1Chong Kun Dang PharmaceuticalNCT04706286Written as CKD-501, D759, D150
- A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04431687Written as CKD 501
- A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150CompletedPhase 1Chong Kun Dang PharmaceuticalNCT04334213Written as CKD-501
- The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 DiabetesStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT03641352Written as CKD-501 0.5mg
- Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesStatus unknownPhase 3Chong Kun Dang PharmaceuticalNCT03627182Written as CKD-501 0.5mg
- Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02007941Written as CKD-501
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownPhase 1Chong Kun Dang PharmaceuticalNCT02854748Written as Lobeglitazone 0.5mg
- CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)CompletedPhase 1Chong Kun Dang PharmaceuticalNCT02824874Written as Duvie Tab. 0.5mg
- A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic FunctionCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02005744Written as CKD-501
- Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersCompletedPhase 1Chong Kun Dang PharmaceuticalNCT02648854Written as CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T
See all 30 studies that test lobeglitazone →
Given in every arm · 4 — lobeglitazone is usual care beside what is tested
- Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05113693Written as CKD-501, D759, H053
- A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed ConditionsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05347576Written as CKD-501, D759, D150, D029
- Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mgCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04869800Written as CKD-501, D745
- Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy SubjectsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT04260438Written as CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T
As the comparator · 1 — what is tested is compared with lobeglitazone
Codes
What other systems call lobeglitazone · ClinicalTrials.gg INT005553
- MeSH (NLM) C546215lobeglitazoneOne source NLM
- UNII (FDA) MY89F08K5DLOBEGLITAZONEConfirmed FDA, NLM, Wikidata
- Wikidata Q18350076(RS)-lobeglitazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C91021LobeglitazoneOne source FDA
- DrugBank DB09198One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546215 | lobeglitazone | One source NLM |
| UNII (FDA) | MY89F08K5D | LOBEGLITAZONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18350076 | (RS)-lobeglitazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C91021 | Lobeglitazone | One source FDA |
| DrugBank | DB09198 | — | One source Wikidata |
Also registered as lobeglitazone sulfate (UNII 95C712E83P).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.